News
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the ...
1h
Zacks Investment Research on MSNSarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue EstimatesSarepta Therapeutics (SRPT) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.07 per share a year ago. These ...
Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
7hOpinion
The New Republic on MSNPete Hegseth Unveils Return of Pro-Slavery MonumentU.S. Defense Secretary Pete Hegseth announced Tuesday that a Confederate memorial would be reinstalled in Arlington Cemetery ...
15hOpinion
The New Republic on MSNTrump Manages to Be Racist While Admitting He’s Wrecking FarmsTrump appeared to acknowledge in the interview that his ruthless mass deportation campaign is hurting farms, which rely on ...
This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.
George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results